French drugmaker Sanofi said ​on Thursday it ‌would pay US partner Regeneron $1 billion ​upfront and ​up to $7 billion more ⁠in milestone ​payments to add ​four next-generation, long-acting immunology antibodies to the ​partnership behind ​their blockbuster eczema drug ‌Dupixent.